Regeneron
FDA rejects Sarilumab due to production facility issues
October 31, 2016Manufacturing and Production, Sales and Marketing FDA, Regeneron, Sanofi, sarilumab
The US Food and Drugs administration has decided to reject the application for Sarilumab, Regeneron and Sanofi’s rheumatoid arthritis treatment, …
Regeneron and Teva’s experimental drug halted by FDA clinical hold
October 17, 2016Manufacturing and Production Regeneron, Teva, back pain, osteoarthritis
Regeneron Pharmaceuticals and Teva Pharmaceuticals had only just agreed a deal worth a potential $2.6 billion to co-develop Regeneron’s fasinumab …
Regeneron’s Eylea fails combination study endpoint
October 3, 2016Research and Development, Sales and Marketing Eylea, Regeneron
Regeneron has announced that its eye drug Eylea (aflibercept) failed its primary endpoint in a mid-stage trial investigating its effectiveness …
Teva and Regeneron team up for $2.6 billion pain treatment development
September 21, 2016Research and Development, Sales and Marketing Regeneron, Teva, fasinumab, osteoarthritis
Teva and Regeneron have entered an agreement worth up to $2.6 billion to develop and market the latter’s experimental nerve …
Sanofi & Regeneron’s Praluent cholesterol treatment smashes Phase III target
August 30, 2016Manufacturing and Production, Research and Development Regeneron, Sanofi, apheresis, cholesterol, phase III
Sanofi and Regeneron have announced that their Praluent injection generated positive Phase III results investigating patients with an inherited form …
Amgen, Sanofi cholesterol medicines “not cost-effective”, need to drop price by two-thirds
August 17, 2016Research and Development, Sales and Marketing Amgen, QALY, Regeneron, Repatha, Sanofi, cost effective, cost-effective, praluent
A new study published in JAMA has suggested that Amgen, Sanofi and Regeneron would have to reduce their prices for …
Eylea sales jump helps boost Regeneron in Q2 results
August 5, 2016Medical Communications, Research and Development 2016, Eylea, Q2, Regeneron, results
Regeneron Pharmaceuticals has published positive Q2 results with a 27% rise in Eylea (aflibercept) sales in the US helping to …
EMA accepts MMA for rheumatoid arthritis treatment Sarilumab
August 1, 2016Research and Development, Sales and Marketing EMA, MAA, Regeneron, Sanofi, sarilumab
Sanofi and Regeneron Pharmaceuticals have announced that the European Medicines Agency (EMA) has accepted the Marketing Authorisation Application (MAA) for …
Sanofi, Regeneron say cholesterol drug Praluent approved in Japan
July 5, 2016Manufacturing and Production, Research and Development, Sales and Marketing Japan, Regeneron, Sanofi, cardiovascular, cholestrol, praleunt
Sanofi (Euronext: SAN) and Regeneron Pharmaceuticals (Nasdaq: REGN) said the lawmakers in Japan have granted marketing and manufacturing authorization for …
Sanofi and Regeneron combo shows superiority in late-stage atopic dermatitis trials
June 6, 2016Research and Development, Sales and Marketing Dupilumab, Regeneron, Sanofi, atopic dermatitis, late stage trials
Sanofi (NYSE: SNY) and Regeneron (NASDAQ: REGN) have announced positive results from a Phase III trial evaluating dupilumab in patients …
Research shows Novartis’s Entresto reduces cardiovascular death and heart failure
April 4, 2016Research and Development, Sales and Marketing Entresto, Novartis, Regeneron, Sanofi, cardiovascular, clinical trial, patent
Novartis has announced results from the PARADIGM-HF clinical trial that show that Entresto (sacubitril/valsartan) consistently demonstrated benefit among heart failure …
Sanofi and Regeneron announce positive Phase III trial results for chronic skin disease treatment
April 1, 2016Medical Communications, Research and Development Dupilumab, Regeneron, Sanofi, atopic dermatitis, phase III, skin disease
Sanofi (NYSE: SNY) and Regeneron Pharmaceuticals (NASDAQ: REGN) have announced positive top line results for dupilumab in Phase III clinical …
Sanofi and Regeneron meet endpoint in Phase III Praluent study
March 23, 2016Research and Development Regeneron, Sanofi, endpoint, escape, hefh, odyssey, phase 3, phase III, positive, praulent, trial
Sanofi and Regeneron Pharmaceuticals have announced that their Phase III ODYSSEY ESCAPE clinical trial evaluating Praluent (alirocumab) met its primary …
Amgen wins high-profile cholesterol drug patent case v Sanofi
March 17, 2016Sales and Marketing Amgen, PCSK9, Regeneron, Repatha, Sanofi, cholesterol, praluent
A Delaware district court jury has ruled in favour of Amgen in an ongoing dispute around patents for cholesterol-lowering drugs …
Sanofi says its RA drug bested Humira in Phase III study
March 11, 2016Medical Communications, Research and Development Humira, Regeneron, Sanofi
Sanofi and its R&D arm Regeneron Pharmaceuticals say their monoclonal antibody sarilumab outperformed AbbVie’s Humira in treating the symptoms of …
